The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Abstract
Purpose: To identify the criteria for hematologic and cardiac response to treatment in immunoglobulin light chain (AL) amyloidosis based on survival analysis of a large patient population. Patients and Methods: We gathered for analysis 816 patients with AL amyloidosis from seven referral centers in the European Union and the United States. A different cohort of 374 patients prospectively evaluated at the Pavia Amyloidosis Research and Treatment Center was used for validation. Data was available for all patients before and 3 and/or 6 months after initiation of first-line therapy. The prognostic relevance of different criteria for hematologic and cardiac response was assessed. Results: There was a strong correlation between the extent of reduction of amyloidogenic free light chains (FLCs) and improvement in survival. This allowed the identification of four levels of response: amyloid complete response (normal FLC ratio and negative serum and urine immunofixation), very good partial response (difference between involved and uninvolved FLCs [dFLC] < 40 mg/L), partial response (dFLC decrease > 50%), and no response. Cardiac involvement is the major determinant of survival, and changes in cardiac function after therapy can be reliably assessed using the cardiac biomarker N-terminal natriuretic peptide type B (NT-proBNP). Changes in FLC and NT-proBNP predicted survival as early as 3 months after treatment initiation. Conclusion: This study identifies and validates new criteria for response to first-line treatment in AL amyloidosis, based on their association with survival in large patient populations, and offers surrogate end points for clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Self-citationAnalysis of survival by tumor response.
Anderson, J. R., Cain, K. C., & Gelber, R. D. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.710 · Cited by 1,107
Analysis of survival by tumor response.
Anderson, J. R., & Davis, R. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.115 · Cited by 1,000
Dispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Self-citationMerlini, G., & Stone, M. J. (2006) · Blood · doi:10.1182/blood-2006-03-001164 · Cited by 463
Self-citationLachmann, H. J., Gallimore, R., Gillmore, J. D., Carr‐Smith, H. D., Bradwell, A. R., Pepys, M. B., & Hawkins, P. N. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04433.x · Cited by 435
Self-citationSurvival in patients with primary systemic amyloidosis and raised serum cardiac troponins
Dispenzieri, A., Kyle, R. A., Gertz, M. A., Therneau, T. M., Miller, W. L., Chandrasekaran, K., McConnell, J. P., Burritt, M. F., & Jaffe, A. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13396-x · Cited by 317
Self-citationPalladini, G., Lavatelli, F., Russo, P., Perlini, S., Perfetti, V., Bosoni, T., Obici, L., Bradwell, A. R., D'Eril, G. M., Fogari, R., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4385 · Cited by 311
Self-citationPalladini, G. O., Russo, P., Bosoni, T., Verga, L., Sarais, G., Lavatelli, F., Nuvolone, M., Obici, L. P., Casarini, S., Donadei, S., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.117143 · Cited by 281
Self-citationWu, A. H. B., Smith, A. M., Wieczorek, S. J., Mather, J. F., Duncan, B. H., White, C. M., McGill, C. C., Katten, D. M., & Heller, G. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00741-0 · Cited by 260
Cited by
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Self-citationDaratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028631 · Cited by 702
Self-citationSystemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citationLeung, N., Bridoux, F., Batuman, V., Chaidos, A., Cockwell, P., D’Agati, V. D., Dispenzieri, A., Fervenza, F. C., Fermand, J.-P., Gibbs, S., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0077-4 · Cited by 551
Self-citationAddressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Self-citationPalladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., Basset, M., Hawkins, P., Merlini, G., & Wechalekar, A. D. (2015) · Blood · doi:10.1182/blood-2015-01-620302 · Cited by 450
Self-citationDiagnosis of monoclonal gammopathy of renal significance
Bridoux, F., on behalf of the International Kidney and Monoclonal Gammopathy Research Group, Leung, N., Hutchison, C. A., Touchard, G., Sethi, S., Fermand, J.-P., Picken, M. M., Herrera, G. A., Kastritis, E., et al. (2015) · Kidney International · doi:10.1038/ki.2014.408 · Cited by 426
Self-citationEpidemiology of AL amyloidosis: a real-world study using US claims data
Quock, T. P., Yan, T., Chang, E., Guthrie, S., & Broder, M. S. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016402 · Cited by 416
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Gertz, M. A., & Dispenzieri, A. (2020) · JAMA · doi:10.1001/jama.2020.5493 · Cited by 366
Self-citationMuchtar, E., Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dingli, D., Buadi, F. K., Grogan, M., Hayman, S. R., Kapoor, P., Leung, N., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751628 · Cited by 340
Self-citationPatisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300757 · Cited by 339
Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Muchtar, E., Blauwet, L. A., & Gertz, M. A. (2017) · Circulation Research · doi:10.1161/circresaha.117.310982 · Cited by 327
Self-citationSystemic amyloidosis from A (AA) to T (ATTR): a review
Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., Kurtin, P. J., Leung, N., Buadi, F. K., Dingli, D., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13169 · Cited by 327
Self-citationHow I treat monoclonal gammopathy of renal significance (MGRS)
Fermand, J.-P., Bridoux, F., Kyle, R. A., Kastritis, E., Weiss, B. M., Cook, M. A., Drayson, M. T., Dispenzieri, A., & Leung, N. (2013) · Blood · doi:10.1182/blood-2013-05-495929 · Cited by 326
Self-citationPomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
Sanchorawala, V., Shelton, A. C., Lo, S., Varga, C., Sloan, J. M., & Seldin, D. C. (2016) · Blood · doi:10.1182/blood-2016-04-710822 · Cited by 275
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
Afrough, A., Saliba, R. M., Hamdi, A., El Fakih, R., Varma, A., Dinh, Y. T., Rondon, G., Cornelison, A. M., Shah, N. D., Bashir, Q., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.03.025 · Cited by 6
“Previous reports on the outcome of high-dose therapy and auto-HCT in AL have primarily focused on patients with cardiac or renal involvement [13, 14].”
Result
Metadata
- Authors
- Palladini, G., Dispenzieri, A., Gertz, M. A., Kumar, S., Wechalekar, A., Hawkins, P. N., Schönland, S., Hegenbart, U., Comenzo, R., Kastritis, E., Dimopoulos, M. A., Jaccard, A., Klersy, C., & Merlini, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-12-20
- Volume
- 30
- Issue
- 36
- Pages
- 4541-4549
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111080788
- Cited by
- 974
- References
- 24
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.